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Abstract Rapid advances in microarray and sequencing
technologies are making genotyping and genome se-
quencing more affordable and readily available. There
is an expectation that genomic sequencing technologies
improve personalized diagnosis and personalized drug
therapy. Concurrently, provision of direct-to-consumer
genetic testing by commercial providers has enabled in-
dividuals’ direct access to their genomic data. The
expanded availability of genomic data is perceived as
influencing the relationship between the various parties
involved including healthcare professionals, researchers,
patients, individuals, families, industry, and government.
This results in a need to revisit their roles and respon-
sibilities. In a 1-day agenda-setting meeting organized
by the COST Action IS1303 “Citizen’s Health through
public-private Initiatives: Public health, Market and
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Ethical perspectives,” participants discussed the main
challenges associated with the expanded availability of
genomic information, with a specific focus on public-
private partnerships, and provided an outline from
which to discuss in detail the identified challenges.
This paper summarizes the points raised at this meeting
in five main parts and highlights the key cross-cutting
themes. In light of the increasing availability of geno-
mic information, it is expected that this paper will pro-
vide timely direction for future research and policy
making in this area.
Keywords Genomics . Clinical and research genomic data .
Return of results . Data sharing . Informed consent .
Direct-to-consumer genetic testing
Introduction
Rapid advances in microarray and sequencing technologies
are making genotyping and genome sequencing more afford-
able and readily available. The decreasing cost and time need-
ed for sequencing has generated the expectation that the use of
next-generation sequencing technologies (NGS) (i.e., new
high-throughput and massively parallel DNA-sequencing
technologies) will greatly increase in a wide range of contexts
(Rehm 2017). Already, NGS is increasingly used to identify
causative mutations in some patients with rare or undiagnosed
diseases of genetic origin (Levenson 2014). Furthermore, the
expectation has grown that genomic-sequencing technologies
could be applied in a broad range of clinical situations, leading
to personalized diagnoses and personalized drug therapy. Data
arising from genome sequencing is likely to lead to a better
prediction of disease risk and treatment response and the
avoidance of adverse events (Lazaridis et al. 2016; Rehm
2017; Soden et al. 2014; van Zelst-Stams et al. 2014).
Furthermore, it is anticipated that an increasing number of
healthy individuals will use genomic technologies to predict
personal risks (Knoppers et al. 2014; van El et al. 2013). For
over a decade now, genetic testing companies have been mar-
keting and selling genetic tests direct to consumer (DTC) via
the internet (Howard and Borry 2012). A number of online
interpretation services (such as Promethease, LiveWello, and
Interpretome) have also emerged that allow consumers to re-
ceive an analysis of their own raw genomic data received from
these DTC genetic testing companies (Badalato et al. 2017).
These online services will allow for further interpretation of
the user’s genome.
Between 2013 and 2017, the COST Action IS1303
“Citizen’s Health through public-private Initiatives: Public
health, Market and Ethical perspectives” identified and
reunited a community of academic and industry researchers
as well as other stakeholders with expertise in bioethics, social
studies of science and technology, genetics, information and
communication technology, stakeholder deliberation, and
patient-centered initiatives (PCI). As part of this networking
project, a meeting was convened in Leuven (Belgium) on 21
and 22 March 2016, in order to identify and discuss the chal-
lenges related to the expanded availability of genomic infor-
mation in society. A particular focus was placed on the context
of public-private partnerships in genomics. The meeting
aimed to promote a mutually informative and collaborative
agenda-setting process. The aim of this document is to iden-
tify, via horizon scanning, the main forthcoming challenges
and areas of interest arising from the availability of genomic
information in society. It is expected that the results of this
paper will allow for constructive reflection on future develop-
ments and the identification of research priorities. It is de-
signed for use by a wide array of stakeholders, such as regu-
lators, policy makers, healthcare institutions, patient organiza-
tions, and industry.
Current and future challenges were identified in the context
of five salient/key relationships in the realm of genetics and
genomics (Fig. 1): (1) healthcare professionals, patients, and
families; (2) genomic data and its impact on individuals and
families; (3) researchers, research participants, and the general
public; (4) genomics, society, and its values; and (5) industry,
governments, and citizens. An overlap between these different
relationships obviously exists, but they help to frame the
various areas of focus. As well as these overlaps, some
identified challenges are also relevant to more than one type
of relationship.
Healthcare professionals, patients, and families
Developing policies for reporting results The clinical
implementation of NGS technologies creates huge challenges
for laboratories and clinicians at the level of returning results.
The use of NGS for whole exome or whole genome
sequencing has the potential to identify variants in genes for
which the function is unknown or variants for which the
pathogenicity has not been established (Ream and Mikati
2014). Some commentators have concluded that using NGS
may “raise more questions than it answers for some patients”
(Ream and Mikati 2014). In addition to issues related to the
interpretation and reporting of these variants of uncertain
significance (VUS), uncertainty remains regarding how to
deal with incidental findings unrelated to the clinical
indication of the test. This issue is particularly complicated
when the variants relate to late-onset conditions (Katsanis
and Katsanis 2013) or untreatable conditions (Vasta et al.
2012). Such information can also have familial implications
(Babkina and Graham 2014). Different guidelines and
protocols that describe how to handle the return of results, in-
cluding VUS and incidental findings, have been developed and
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need further elaboration as well as potential harmonization,
especially with regard to the pertinent responsibilities of
involved parties (Vears et al. 2017a, b).
Developing appropriate clinical and counseling frame-
works and structures The enhanced technical options for
genetic testing are not yet accompanied by comprehensive
genetic counseling models for the genomic era. New models
and frameworks of genetic counseling that extend beyond the
traditional clinical genetics and genetic counseling setting
need to be developed (Bradbury et al. 2014). Given the poten-
tial of NGS to generate high volumes of data, and uncer-
tainties around results of the data generated, there is a pressing
need to revitalize current genetic counseling services.
Furthermore, individuals receiving sequencing results may
adopt different roles such as patient, customer, hobbyist, or
activist. Previously, individuals largely had a unique and de-
fined pathway for accessing genetic information through the
traditional healthcare setting (via clinical geneticists and/or
genetic counselors) on the basis of specific clinical concerns
or family history. In contrast, individuals now have the
opportunity to choose genetic testing without the intermediary
of a professional assessment of clinical need and can obtain
testing for a variety of purposes, including mere curiosity.
Individuals may also choose to use sequencing services that
provide access to raw data without interpretation, providing
them with “unfiltered” genetic information to use as they see
fit. They could, for example, attempt to “self-interpret” with
the support of publicly available sites for the analysis of ge-
netic data (such as openSNP), or use it for entirely unrelated
purposes, such as artistic endeavors (Werner-Felmayer 2014).
Genetic counseling policies should be developed in relation to
the different ways individuals can access genomic informa-
tion. As part of this, it is important to (re)define the roles of
clinical geneticists, genetic/genomic counselors, and other
professionals, such as general practitioners specialized in clin-
ical genetics who provide advice in relation to the wide array
of genomic information (Middleton et al. 2015).
Training healthcare professionals so they understand ge-
nomics and its role in healthcare In the clinical setting, even
among genetic experts, there is a clear need for a collaborative,
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Fig. 1 Five salient/key
relationships in the realm of
genetics and genomics and the
central cross-cutting themes
J Community Genet (2018) 9:103–116 105
multidisciplinary effort (biology, bioinformatics, clinical ge-
netics) to interpret and understand NGS results. As genomics
continues to move from specialized centers to mainstream
medicine, various medical specialists who are unfamiliar with
clinical genetics or genetic counseling may be increasingly
required to have a greater role in the prescribing and/or inter-
pretation of genetic testing and the communication of geno-
mic information. For instance, Gen-Equip (Paneque et al.
2017; Primary Care Genetics) is an example of an effort that
has beenmade to enable health professionals who are working
in primary care to update their knowledge and skills in genet-
ics. The Gen-Equip project (https://www.primarycaregenetics.
org) was co-funded by the EU Erasmus+ Programme. It de-
veloped a program of online learning modules and tools to
support daily practice in primary care about genetics.
It will be necessary to educate and train healthcare profes-
sionals to translate this changing landscape into appropriate
patient care, including being family-centered. Authors have
identified a need for a new kind of physician who will be
trained in several disciplines including medicine, genetics,
and counseling (Gonzalez-Garay et al. 2013; Iacobazzi et al.
2014). Others advocate either for clinical geneticists to have a
more prominent role in the clinical interpretation of data
(Gomez-Lobo 2014; Grody et al. 2013) or for several experts
such as “molecular biologists, clinical geneticists, and
bioinformaticists” to combine their efforts for data interpreta-
tion (Grody et al. 2013). The implementation of NGS is no
longer viewed as an individual physician’s endeavor, and
therefore clinics offering genomic testing will need to adapt
to this increased need for cross-disciplinary collaboration
(Rigter et al. 2013), including conducting ethical, legal, and
social issues research to accompany the clinical advances,
especially while roles for laboratory geneticists and clinicians
are changing.
Identifying the ethical and legal responsibilities of
healthcare professionals towards families Healthcare pro-
fessionals are increasingly asked for advice about the commu-
nication of genetic risk information to individuals as well as
regarding communication within families. Based on the pre-
mise of medical confidentiality, professional guidelines rec-
ommend that professionals should not contact a client’s family
members directly (Forrest et al. 2007) without his or her ap-
proval. Adherence to this guideline means that the client’s
wish to disclose (or not disclose) information to relatives,
must be respected (Hodgson and Gaff 2013). However, these
guidelines also state that professionals should actively encour-
age clients to transmit relevant risk information to relatives
and support them throughout the communication process
(Forrest et al. 2007). When clients fail to disclose important
information to relatives, professionals are confronted with po-
tential ethical tensions between, on the one hand, addressing
the needs of the individual and his/her right to confidentiality,
and on the other hand, considering the potential for harm to
uninformed relatives (Dheensa et al. 2015a). Some have rec-
ommended a more proactive role for health professionals
(Battistuzzi et al. 2012; Otlowski 2013), although there is lack
of clarity regarding how this could be achieved. Legislative
frameworks in countries such as France, Australia, and
Norway have created mechanisms that provide healthcare pro-
fessionals with the potential to override their patients’ confi-
dentiality in the interests of their relatives (Dheensa et al.
2015b; D’Audiffret van Haecke and de Montgolfier 2016;
Weaver 2016). It is important to study the impact of these
legislative changes and to consider whether they should be
implemented more widely. The fact that such large volumes
of data can be generated about patients also raises the question
of whether there is a duty for health professionals to re-contact
former patients should new genomic findings of potential clin-
ical relevance come to light (Carrieri et al. 2017b). Although
disclosing these findings may offer novel and more effective
diagnostic/clinical options to the patient, re-contact also has
the potential to cause anxiety and alarm to recipients of this
new information, and their families, and may be logistically
very difficult to achieve in practice. This highlights the need to
explore the attitudes of individuals regarding communication
of risks to their families as well as the factors that influence
them towards a course of action. This also raises questions
about the level of confidence of health professionals in
performing the proposed practices, the provision of necessary
funding and resources for these activities, as well as the crea-
tion of the necessary infrastructure to accommodate said prac-
tices. This might include updated registries, patient portals,
other forms of consent, mobilization of patients’ associations
in order to sensitize patients to regularly contacting genetic
services, providing ongoing training for the genetic counsel-
ing workforce, and being open to adopting novel approaches
if needed (Carrieri et al. 2017a).
The impact of genomic data on individuals
and families
Identifying strategies for offering appropriate, informed
choices to patients In light of the new potential applications
arising from using NGS in healthcare, various challenges re-
main with regard to obtaining informed consent, the reporting
of results, and the inclusion of patient preferences regarding the
return of results (Budin-Ljøsne et al. 2016). Determining which
results should be returned, including incidental findings and
VUS, following the use of NGS for diagnostic purposes, poses
challenges for laboratories and clinicians (see below). It also
poses challenges for individuals and families in making (truly)
informed decisions with regard to the results they wish to re-
ceive. Indeed, they may not have enough information and/or
understanding to support such a truly informed decision. More
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research is required to develop appropriate strategies to explain
the different types of results that could be generated, and the
related uncertainties before a test. Research also needs to be
performed regarding how best to report results to patients, in-
cluding how to support probands to discuss, these results with
family members (Daly et al. 2016; de Geus et al. 2016), if
necessary. This approach should include discussion among dif-
ferent stakeholders, as well as careful consideration of the im-
pact that reporting strategies could create in both patient popu-
lations and the general public, and with regard to the potential
costs to the healthcare system. The access to genomic medicine
will also increasingly be available throughout the lifespan, from
conception to elderly care. Individuals will be confronted with
increasing technological possibilities and related informed
choices to be made in various types to situations, such as
preconceptional carrier screening, prenatal testing, preimplan-
tation genetic diagnosis, newborn screening, tumor profiling, or
genomic risk assessments in adult life (Rehm 2017).
Identifying strategies to support interfamilial genetic com-
municationClinical genetic healthcare providers have always
strongly emphasized the familial nature of genetic informa-
tion, and this has, in turn, guided patients’ use of these genetic
services. Emphasis has mainly been placed on helping the
individual understand testing, obtaining consent, and
returning the results of testing to the individual. Less attention
has been given to how to help these individuals respond to
their genetic information, particularly when considering the
shared nature of genetic information. As genetic sequencing
and testing also has implications for relatives, genetic
healthcare services have the challenge of supporting families,
not just individuals (Eisler et al. 2017). Sequencing whole
genomes/exomes potentially increases the need to involve
family members to clarify inconclusive test results (newly-
discovered variants and variants of uncertain significance)
(Hallowell et al. 2015). Therefore, more research is required
to explore the following: how families cope with genetic in-
formation; to what extent barriers exist relating to the disclo-
sure of genetic information within families; and how such
information impacts interfamilial relations. Although patients
might initially feel inclined to transmit genetic risk informa-
tion to their relatives, in reality, sharing of this information can
be problematic. Individual perspectives, patterns of family
dynamics, disease characteristics, and cultural factors may
cause individuals to withhold or delay the disclosure of geno-
mic information to at-risk relatives (Daly et al. 2016; de Geus
et al. 2016; Vos et al. 2011). It has been argued that genetic
information pushes the boundaries of individual autonomy
from pure independence to a more relational approach to fam-
ily responsibility (Widdows 2013). Such approaches stress the
balance between rights, responsibilities, and the autonomy of
individuals dealing with their own genetic information and the
way these considerations intertwine with those of a family
(Dheensa et al. 2016). Patients may also be unsure of the
responsibilities of the healthcare professionals who have been
involved in their diagnosis—some patients believe that their
clinician is responsible for informing their relatives, rather
than the patient themself (Mesters et al. 2005).
Understanding the impact of genomic information on in-
dividual identity The increasing availability of genomic in-
formation, within and outside the context of the traditional
healthcare system (i.e., via direct-to-consumer genetic testing
companies), provides new opportunities for individuals to en-
gage with this information (O’Riordan 2016). Individuals are
now able to have their own genetic data interpreted by all
kinds of third-party interpretation services, outside of a clini-
cal context. Healthcare professionals will increasingly being
challenged by requests from individuals to help interpret ge-
netic information that was obtained outside a traditional con-
text. This might put pressure on healthcare systems, as a lot of
this information might be of limited clinical validity and utility
and, in most of the cases, genetic testing was not on medical
indication (McGuire and Burke 2011).
Moreover, genomic information opens up new avenues for
integrating genomic information into individuals’ conceptions
of “self” (Novas and Rose 2000). A “balancing” of the per-
ceptions of one’s “genetic side” as compared with one’s “as-
pects of oneself” also has relevance not only for personal
identity, but for expectations, concerns, hopes, and decisions
regarding genetic/genomic information, technologies, and ser-
vices. Genetic informationmay be perceived as an exceptional
window into our deep identity or may be seen as just one of
many sources of information about the “self.” Further research
is needed to understand the impact of genomic information on
patients and families both within and outside the healthcare
system.
Researchers, research participants, and the general
public
Enabling data sharing while respecting ethical safeguards
In order to facilitate public health research, a diverse group of
international and national funders of health research agreed to
promote “greater access to and use of data” in equitable, eth-
ical, and efficient ways (Walport and Brest 2011). More spe-
cifically in genetics and genomics, international and national
policies and guidelines have established general frameworks
to guide researchers in their data-sharing endeavors (Expert
Advisory Group on Data Access 2015; Human Genome
Organisation 1996; National Institutes of Health 2014; The
Organisation for Economic Cooperation and Development
2007). Biomedical journals have also increasingly made data
sharing a condition of publication (Barbui 2016; Barsh et al.
2015). In order to enable scientific advances, various
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publications have argued for the identification and removal of
practical, legislative, professional, institutional, and attitudinal
obstacles in order to achieve large-scale creation, access, and
integration of data with sufficient sustainability (Burn 2016;
Majumder et al. 2016; Wilbanks and Friend 2016). Regarding
sharing practices to facilitate downstream uses of data, it is
important to ensure that the rights of all parties involved
(namely members of the general public, research participants,
and their families, researchers, and funding bodies) are
respected (Williams and Pigeot 2017). Data sharing, and ge-
nomic data-intensive research in general, may trigger con-
cerns that differ considerably from concerns regarding re-
search with human participants, which traditionally tend to
be associated with physical risks. In particular, processing
sensitive genomic data may raise informational risks for the
data subjects, their family members or ethnic groups. Use of
genomic data in a discriminatory manner by third parties, such
as insurance companies or employers, is a prime example of
the unintended consequences of processing genomic data.
Consequently, employing a tailored approach to protect the
rights of research participants is necessary (Shabani et al.
2014). Data-sharing policies should create mechanisms to re-
inforce the accountability of the researchers and data users,
thereby ensuring that robust procedures are in place to govern
data sharing and to respond to data misuses in an adequate
manner (Lemke et al. 2010; Trinidad et al. 2010). Policies
should endeavor to establish transparent, fair, and objective
access and sharing procedures in order to ensure responsible
data sharing (Shabani et al. 2015a), and to avoid unintended
secondary uses of the data (O’Doherty et al. 2016). At the
moment, data-sharing policies are mostly developed within
the context of research projects by funders (e.g., NIH,
Wellcome Trust) but are often not harmonized across projects
and have a limited outreach (Budin-Ljøsne et al. 2014). For
instance, they often do not provide guidance on how data
produced within a project should be governed after project
completion (Bobrow 2015). Furthermore, data sharing for
clinical data is needed for optimal interpretation of variants
(Hayden 2012).
Importantly, sharing individual-level genomic data also
fuels concerns regarding the privacy of data subjects
(Rothstein 2010). Privacy breaches resulting from re-
identification of data could lead to harm for individuals and
undermine public trust on the robustness of the data protection
measures adopted by research institutions. Furthermore, while
stand-alone anonymized genomic information is currently dif-
ficult to re-identify, such re-identification is not impossible.
That being said, to date, the reported incidence of re-
identification of genomic data has been limited, often requir-
ing high levels of expertise (Gymrek et al. 2013; Homer et al.
2008; Shringarpure and Bustamante 2015). Nevertheless, the
evolving potential of genomics and bioinformatics makes the
risks of re-identification and/or privacy breaches moving
targets, thereby requiring ongoing monitoring of the field
and assessment of the sufficiency of the pertinent legal, ethi-
cal, and practical safeguards in place. The importance of
adopting organizational and technical safeguards has been
highlighted in the recent General Data Protection Regulation
(GDPR). While GDPR suggests technical measures such as
pseuonymization as an example of safeguards, it is crucial to
further elaborate the additional organizational and technical
measures to safeguard research participants and patients in
the view of sensitive health and genomic data processing.
Adapting oversight and governancemechanisms for geno-
mic research Current models of research governance were
created at a time when research was often conducted at one
site, by one team and involved a limited number of partici-
pants. These days, much of research is often multi-sited, in-
ternational (e.g., research consortia) and organizationally
complex (Kaye 2011; Kaye and Hawkins 2014). Effective
and flexible research governance models that are harmonized
across jurisdictions are required to meet the needs of current
research approaches. Mechanisms are needed that enable
greater transparency and allow for a greater involvement of
research participants (Homer et al. 2008; Kaye et al. 2015a;
Williams et al. 2015). Data access oversight bodies are exam-
ples of new governance tools that might be able to ensure
appropriate monitoring of secondary research uses of data
(Shabani et al. 2015b). Data access committees could maintain
oversight of downstream data uses which are not yet known at
the time of data and sample collection. It is expected that
oversight bodies play a key part in reassuring research partic-
ipants that their data is in safe hands and being used in ways
that benefit science and society or are consistent with the
consent they have given. In doing so, oversight bodies should
adopt fair, objective, and transparent access arrangements.
Assessing innovations in research participation The role of
research participants in genomic research and data sharing is
evolving (Dove et al. 2012). It has been argued that both
research participants and researchers would benefit from the
active involvement of participants in various steps of the re-
search process, from data collection to the management of
data access (Erlich et al. 2014), and also obtaining their input
when developing research policies (Pomey et al. 2015). Some
have argued that by using the potential of various online plat-
forms, individuals’ ongoing interactions with researchers, re-
search institutions and other participants would be facilitated.
DNA.LAND, Free The Data, and Patients Like Me exemplify
initiatives that enable a broad scope of research participation
by individuals, including sharing personal genomic and
health-related data. The potential challenges to research ethics
principles of adopting such approaches require further explo-
ration (Shabani and Borry 2015). Individuals should have suf-
ficient understanding of the research procedure and the
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associated risks and benefits to ensure informed decision mak-
ing (Pereira et al. 2014). In particular, concerns exist with
regard to the sharing of genomic data with biotech and phar-
maceutical companies (Roberts et al. 2017). Questions also
exist with regard to the transparency of such data sharing,
the appropriateness of used informed consent and the potential
lack of ethics approval (Niemiec and Howard 2016).
Assessing innovations at the level of informed consent
Ideally, consent for healthcare procedures is a dynamic pro-
cess, with an emphasis on disclosure of relevant information
to the client, and then assessing the client’s understanding of
the information and their ability to communicate their consent
(Appelbaum 2007). In practice, consent for genetic testing
often involves a punctual/one off process whereby experts
provide information to participants, who then sign a paper-
based consent form. However, this approach may be insuffi-
cient to inform research participants about the scope of re-
search and the associated risks and benefits (Hayden 2012).
The perceived shortcomings of this approach have led some to
conclude that the current consent process, including the forms,
are insufficient, and thus adopting alternative approaches ap-
pears inevitable (Hayden 2012). Alternative models, such as
dynamic consent, have been suggested in order to introduce
more flexibility to the consent process (Budin-Ljøsne et al.
2017; Kaye et al. 2015b). While these new consent models
have potentially beneficial aspects in addition to obtaining and
maintaining valid consent, such as increased participant en-
gagement (Teare et al. 2015), they still need further research
and analysis (Mascalzoni et al. 2008).
Genomics, society, and its values
Minimizing and avoiding negative disruptive uses and im-
pact of genetic information Little is known about how indi-
viduals or societies at large deal with genomic testing infor-
mation or how such information impacts social relations (for
example, when information is found about predispositions to
stigmatizing diseases such as mental disorders (Gershon and
Alliey-Rodriguez 2013) or cancer (Tercyak et al. 2013)).
Stigmatization based on genomic information, whether it is
based on genomic markers for ethnicity or disease, is a con-
cern and steps should be taken to ensure that genomic infor-
mation is not disruptive at either the familial or societal levels.
Genomic information may be used to discriminate against
individuals and their families (for example, in the work place
or by insurers) on the basis of their genetic profile/genetic risk
predisposition. Cases already exist of discrimination based on
information produced through the genetic screening of new-
borns (Levenson 2016). Some groups, such as ethnic minori-
ties (Joly et al. 2014) and future generations/offspring, may be
particularly exposed to genetic discrimination. Indigenous
peoples can also be exposed to genetic stigma and discrimi-
nation, and mechanisms to mitigate this need to be developed
(Arias et al. 2016). Finally, human rights infringements can
occur in countries which aim to collect the DNA from all of
their citizens in order to develop forensic databases (as exem-
plified by the recent case of Kuwait) (O’Doherty et al. 2016;
Thielking 2016).
Equity and fairness in service provision and access to ben-
efits of genomic technologies Recent developments have re-
sulted in an increase in the number of genetic tests available
and a decrease in the price of genome sequencing. Therefore,
the number of people who could access and potentially benefit
from genetic testing is larger than ever (Rehm 2017).
However, few studies describe to what extent the population
for whom clinical benefit can be achieved is adequately
served. There is a possibility that only those people who can
personally afford the testing, or who are included in research
projects, would undergo testing, such as a relatively high pro-
portion of highly educated people in affluent countries. This
raises serious ethical issues around the inequality of access to
genomic healthcare. Authors who describe the reduced cost of
sequencing, such as the $1000 genome, rarely mention the
additional human resource costs involved in interpretation
and downstream clinical care (Morrison et al. 2014). Given
the financial constraints in healthcare systems, if not all
services/technologies can be covered, criteria should be devel-
oped to determine which genetic services or genetic testing
technologies should be funded from public budgets (Severin
et al. 2015). Prioritization of genetic testing should be based
on considerations of medical benefit, health need,
empowering life-time decision making, and costs (Severin
et al. 2015). However, the demands of fairness and equity
(as with concerns over inequalities of access) may be more
complicated and in need of more carefully nuanced responses
than may initially appear. There is a general underlying con-
cern that is related to the idea that should differential access to
genetic technologies be allowed for those who are able to pay,
it would give rise to new forms of unfairness and unjust in-
equalities—indeed, a key concern for many is how it would
affect the central notion of equality of opportunity in society.
Nevertheless, simply restricting differential access may be
problematic from the point of view of overall utility (leveling
down where not accessible to all) and requiring equal or uni-
versal access (or even reasonable approximations of either in
the near term) may not be feasible when we are talking about a
highly expensive (and to many extents limited) good that has
to be weighed against other priorities in any public budget
(e.g., with regard to education, general healthcare, water treat-
ment, infrastructure, housing, etc.) (Farrelly 2007).
Conversely, while Crozier and Hajzler (2010) note that many
would view market forces as conflicting with the public good,
they also highlight the role of such forces in promoting this
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good by widening access to the technologies in question. The
market, they suggest, would advance the access by those less
well-off to genetic technology through the market stimulus
achieved by the wealthy gaining such access at an earlier point
(Crozier and Hajzler 2010). An ideal egalitarian scenario that
would not give proper scope to the potential role of the private
sector and of private incentives (usually via the notion of
“profit”) could be an overtly romanticized idea (Farrelly
2007). Given the feasibility constraints of most western soci-
eties, with limited budgets and a costly technology (while
reducing in cost, it is still relatively costly, especially taking
into account all steps involved), including a role for the private
sector, via a regulatory framework that permits some
innovation-friendly incentive-based inequalities in access,
may be the best approximation of long-term fairness and
equity.
Linking genomic data to other data sources A particular
concern about data use in genomics refers to the continuously
developing possibilities of interpreting and understanding ge-
nomic information. Given the exponential growth in data stor-
age capacities and computational infrastructure, the integra-
tion of genomic data into the vast amounts of existing data will
provide additional opportunities to capture the significance of
genomics for improvement of health. Data brokers, such as
Axicom, and data holders, such as Google and Facebook,
collect personal information about consumers, and then com-
bine and analyze said data to make inferences about them,
including potentially sensitive inferences. This may infringe
the privacy of individuals and expose them to significant risks
(for instance, because data brokers often store data indefinite-
ly) (Federal Trade Commission 2014). Therefore, adopting
adequate legal safeguards for privacy of the individuals and
addressing pertinent issues, such as intellectual property and
access by the third parties, will be of paramount importance.
Similarly, data brokers are paying attention to the potential
uses of genomic data. The current largest data holders would
be able to connect an analysis of genomic data to an extraor-
dinarily fine-grained and comprehensive set of behavioral and
social information arising from their pervasive services.
Drawing on such a vast repository of “life world”-related in-
formation may allow previously unprecedented opportunities
for the analysis and contextualization of genomic information.
This will create opportunities for new knowledge and insight,
as well as significant potential for abuse. One particular con-
cern in this context is the impact of the availability of such
information on data privacy. As vast quantities and types of
data, including face and fingerprint recognition, keyboard typ-
ing or other web surfing habits, consumer characteristics, and
genome predictions, are available to a large number of com-
mercial stakeholders, these stakeholders can cross link distant
data sources (Wjst 2010). Genomic information is likely to
become part of that integrated picture, especially if it is shared
via the Internet and outside protected spaces. Accordingly,
genetic privacy is becoming increasingly less likely in the
long-term. A general issue that this raises concerns the conse-
quences of a shift in power whereby those who are gathering,
cross-linking and analyzing the digital footprints of individ-
uals may have more knowledge about the individual than the
individual herself (Lupton 2015). While the unprecedented
availability of this amount of data may be a type of “holy
grail” for data researchers, it poses many ethical challenges
that extend beyond the practical/technical challenges of the
development of hardware capable of dealing with the amount
of data. In addition, the increasing use of algorithms in the
health care setting raise questions about accountability of the
users and potential risks for the data subjects (Mittelstadt and
Floridi 2016).
Industry, governments, and citizens
Balancing public and private interests The past decade has
witnessed the rapid development of genomics research.
Industry has played an important role in both the development
of genomic research and the translation from research to clin-
ical practice (Zerhouni et al. 2007). Policy makers have en-
dorsed collaborations between public and private partners
with the goal of stimulating innovation and the economy, cre-
ating jobs, and achieving a faster implementation of new tech-
nologies (Department of Health UK 2013). However, the in-
teraction between public and private actors is also associated
with ethical and social challenges. Finding balances between
public and private interests has been a long lasting difficulty in
human genetics (Contreras 2014). Symbolic of this was the
competition between the public consortium of the
International Human Genome Project and the private compa-
ny Celera Genomics, to see which could sequence the human
genome first. Discussions have also revolved around genetic
disease patents, such as the Association for Molecular
Pathology vs. Myriad Genetics (2013) and the Greenberg v.
Miami Children’s Hospital Research Institute cases (Sterckx
and Cockbain 2016). Furthermore, various debates have de-
veloped about the access of commercial companies to
population-based biobanks, such as deCODE genetics in
Iceland (Árnason and Andersen 2013). In December 2016,
academic institutions met in court to decide on gene editing
patents, potentially worth billions. Although these various
cases highlight different problems, they all illustrate the chal-
lenge of finding a balance between, on the one hand, stimu-
lating research and innovation, and, on the other hand, pro-
moting ethical values such as trustworthiness, respect for au-
tonomy, transparency, and respect for confidentiality and pri-
vacy. Similarly, involvement of industry raises concerns about
how to reconcile private and public interests in an
adequate manner. For many examples in medicine (e.g.,
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medications) it is clear that without industry involvement,
diagnostic and therapeutic advances would not have been
translated as quickly into clinical practice (Hawkins et al.
2009). However, the involvement of industry and commer-
cialization brings challenges relating to trust (Chalmers and
Nicol 2004), knowledge exclusion, trade secrets, and monop-
olies (Hong andWalsh 2009; Mitchell et al. 2011), intellectual
property, conflict of interests, data sharing, informed consent,
privacy, and confidentiality. Policy developments in the do-
main of human genetics should aim to maximize public ben-
efit while allowing a level of intellectual property protection
that is reasonably necessary to achieve that benefit. It should
also be noted that while the inclusion of private interests and
forms of incentive can be beneficial for fostering innovation
and, thereby, widening access (albeit unequally), the
balancing of such public and private interests can have a neg-
ative effect on levels of self-interest and altrustic motivations
in society more generally and so would also be a reason for
limiting any unqualified embrace of the private sector as a
reliable means of promoting access for all in the longer term
(Feeney 2012).
Defining appropriate policies with regard to direct-to-
consumer genetic testing For over a decade, genetic testing
companies have been marketing and selling genetic tests di-
rectly to consumers. This offer happens via the Internet, and
often bypasses the traditional healthcare system and any
healthcare professional involvement; due to these reasons,
and more, DTC companies have been a source of controversy
in academic and policy debates (Howard and Borry 2012).
While the size of the DTC genetic testing market remains
largely unknown (except for 23 and me), it is probably rela-
tively small. On the one hand, many companies that once sold
DTC genetic tests have left the market. Various companies
now collaborate with physicians and the traditional healthcare
system, and have distanced themselves from a consumer-
driven access model. On the other hand, as genetic testing
has become much more affordable over the years and genetic
testing has become more socially acceptable, various compa-
nies have remained in the field. A review of public and orga-
nizational policies on DTC indicated there was no uniform
approach, with some professional organizations warning of
harms and others supporting autonomous choice (Skirton
et al. 2012). Although a new In Vitro Diagnostics (IVD)
Regulation was voted at the European level and will come
in to force in 2022, for regulators at the national level, the
issue of DTC genetic testing will certainly remain on the
agenda for the coming years. A first important policy ques-
tion is the extent to which regulators want to intervene in
the provision of genetic tests. Some have argued that “the
embedding of genetic testing in a healthcare setting can
ensure a context where due emphasis is being provided
on the individualized medical supervision of patients, the
presence of pre-test and post-test counseling, psychologi-
cal evaluation and follow-up if appropriate and quality as-
surance of the tests performed” (Ayme et al. 2013).
However, there are discussions regarding whether this
should also apply to categories of tests that are labeled as
“informational” or “recreational” or that do not offer any
assessment of disease risk (Caulfield et al. 2015). Second,
legislators can also impact the extent to which genetic tests
are occurring within the scope of the healthcare system.
Some countries have developed legislation that does not
allow for direct access to genomic information, and im-
poses canalization of genetic tests through medical doctors
or healthcare professionals (Kalokairinou et al. 2015).
Third, various commentators have proposed a role for reg-
ulatory bodies in imposing and enforcing “truth in adver-
tising” requirements in order to respond to the concerns
relating to inaccurate information provision and subse-
quent consumer misunderstanding concerning the validity
and utility of genomic information provided (EASAC and
FEAM Working Group 2012). Fourth, the development of
educational interventions targeted towards healthcare pro-
fessionals and the general public in order to inform these
groups about the lack of scientific validity and relevance of
many of these DTC tests, has been suggested (EASAC and
FEAM Working Group 2012). Finally, any regulation that
would be developed to manage the DTC genetic testing
market would always have to deal with the issue of
(international) enforcement. It remains difficult to apply a
regulatory control on an international market functioning
through the Internet.
Cross-cutting themes
Maintaining trust Various studies have shown that (public)
trust is a cornerstone of participation in genomic research
(Nobile et al. 2013). But trust is also fragile, and efforts need
to be made at the level of information provision, consent pro-
cedures, and governance mechanisms in order for research
participants to develop and maintain trust in research.
Various studies have consistently found that publics have high
levels of trust in universities and government research organi-
zations. However, studies also show that trust in research di-
minishes if the research is funded by industry (Critchley and
Nicol 2009). As knowledge of potential commercial access to
genomic information is known to be a relevant consideration
in the decision to participate in research, transparency regard-
ing commercial use is ethically required (Caulfield et al.
2014). Informed consent is a mechanism that allows individ-
uals to receive information to enable them to participle in
research in a voluntary way. However, informed consent
comes with its limitations and needs to be complemented by
other governance mechanisms that might address societal
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concerns. In order to keep trust in technological innovations, it
is also of crucial importance that appropriate safeguards are in
place in order to protect individuals from inappropriate dis-
crimination and stigmatization based on genetic information,
and also human rights more broadly.
Evidence building Despite technological progress, there is
still a wide gap between the DNA sequence data than can be
generated and our ability to both interpret sequence variants
and to derive possible health implications from sequence al-
terations in genes (Stemerding and Krom 2013). Although,
clinical implementation of NGS technologies has proven to
be valuable, various challenges remain before routine use of
this technology can occur (Caleshu and Ashley 2016;Manolio
et al. 2013). These include a lack of evidence and conflicting
interpretations of benefit, a lack of institutional and clinical
acceptance, and limited access to genomic medicine and test-
ing. It also includes a lack of standards for genomic applica-
tions such as: integration of genomic results into electronic
medical records and clinical decision support; follow-up of
genotyped patients; outreach to at-risk family members; con-
sent; understanding by patients, clinicians, and public; lack of
access to comparison “control” sequence data and banking
resources; and lack of research funding and reimbursement.
Solutions to these problems are necessary in order to allow
successful and responsible implementation into the clinical
setting. Various commentators have also described the need
for databases that include a comprehensive overview of ge-
netic variants and related phenotypic information. This infor-
mation should be accessible to various clinical groups world-
widewho are involved in interpreting sequence data in clinical
care and research. Many groups are currently doing this in
isolation, and data sharing would benefit many patients
around the world. Policies that reward or require data
sharing should be developed (Cook-Deegan et al. 2013).
Nevertheless, due attention should be paid to the legal require-
ments across jurisdictions that may concern cross-border shar-
ing of genomic data. Furthermore, the views of the public
need to be taken into account (Bentzen and Svantesson
2016; Majumder et al. 2016).
Transferring knowledge to stakeholders
The full potential of the progress being made in genomics and
related fields will not be realized unless the knowledge gen-
erated by such endeavors is translated into a usable format and
transferred to all relevant stakeholders in society. The fore-
most focus should be on how best to inform all relevant stake-
holders about the potential benefits and harms regarding
accessing their genetic information from different sources,
on developing and advertising best practice procedures, and
on facilitating access to genetic knowledge in the most
responsible and ethically acceptable way. As such, education
must address all aspects of the technologies, including ethical
issues and scientific validity. Rapid education and training in
genomics is required for many different practitioners in the
healthcare setting, from scientists and bioinformaticians car-
rying out diagnostic tests, to doctors in non-genetic specialties
who may increasingly order such tests independently of clin-
ical genetics services, to primary care clinicians such as GPs,
specialist nurses, and midwives. Each stakeholder group will
have different educational needs, and training must be prag-
matic and reflect practical needs for certain information rather
than an idealistic goal to upskill everyone significantly in all
aspects of the field.Multi-national coordinated efforts (such as
theMedgen Project or the Gen-Equip project) will be essential
moving for forward in assisting with the mainstreaming and
standardization of genomics into clinical care, as well as im-
proving the visibility of genetics as a whole in the European
context.
Ensuring data security in clinical and research setting
Genetic data is being processed, stored and analyzed on an
unprecedented scale thanks to decreasing costs; ~ 250,000
individual human genomes have been sequenced or are in
progress thus far. Even with conservative estimates of dou-
bling data quantities every 18 months, we will probably reach
massive scale of data generation within the next decade. It is
estimated that by 2025 between 1 and 25% of the eight billion
humans worldwide will have had their genome sequenced
(Stephens et al. 2015). The emerging possibilities for
obtaining and storing genomic information and making it
available to individuals, raise novel challenges with regard
to the security of storage and processing. In many jurisdic-
tions, genetic information is a type of information that receives
special protection and information and communication tech-
nology (ICT) security measures need to meet those require-
ments. Platforms that host or analyze genetic information need
to be equipped against security threats. In particular, the pri-
vacy of the data subjects, integrity of the databases and avail-
ability of the data to authorized users should be reinforced.
Attention needs should be paid, not just to the development of
a secure computing platform, but also to the security of po-
tentially associated cloud providers, the legal protections
cloud services enjoy in their respective jurisdictions, and to
secure and controlled modes of access (Bentzen and
Svantesson 2016). Unfortunately, genome data has a distrib-
uted data architecture where data acquisition is still not stan-
dardized. Instead it involves numerous heterogeneous formats
(Costa 2012) which may raise questions about the data integ-
rity and the adequate safeguards against unauthorized data
uses (Knoppers et al. 2011). Moreover, the issues regarding
the adequate storage and computational infrastructures in a
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widely accessible manner should be taken into consideration.
(Eisenstein 2015).
Conclusion
The expanded availability of genetic information is ex-
pected to influence the relationship between various
parties, including healthcare professionals, individuals,
families, research participants, researchers and industry.
We have highlighted the main challenges arising from
the availability of such information, and suggested areas
for further research. In particular, we have underlined
the significance of maintaining trust, building evidence,
transferring knowledge to stakeholders, and ensuring
data security in clinical and research settings, as the
core elements to be respected in light of the expanded
availabili ty of genomic data and the identified
challenges.
The identified challenges with regard to the expanded
availability of genomic data require various stakeholders to
engage in constructive discussions regarding the best practices
for reporting test results, including reporting incidental find-
ings and VUS. Given the familial implications of genetic data,
it is essential to strike a balance between the rights, responsi-
bilities, and autonomy of individuals dealing with their own
genetic information, and the way these considerations inter-
twine with those of a family. Notably, in dealing with genetic
data, it is essential to respect social values, such as fairness and
justice.
Furthermore, developing adequate tools and guidelines in
order to assist researchers in sharing genetic data is critical.
Informed consent, privacy safeguards and oversight mecha-
nisms should be improved in order to adequately address the
concerns of individuals relating to data sharing and to ensure
the ethical and legal footing of data sharing. Concurrently,
educating both professionals and the general public could raise
awareness regarding the significance of access to geno-
mic data and assist in clarifying the roles and responsibilities
of the parties involved.
The role of regulatory bodies in regulating various aspects
of genetic testing within clinical and research settings is
highlighted by this paper. In particular, regulating various
aspects of commercial direct-to-consumer genetic testing,
including advertisement of the products and the responsibili-
ties of healthcare professionals in dealing with the results of
such tests, are recognized as matters of concern.
The advancements in genomics and bioinformatic technol-
ogies urge an ongoing monitoring of the associated chal-
lenges, and the adequate addressing of them through robust
policies. It is expected that this paper will direct future re-
search and provide grounds for potential policy developments
if needed.
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